SL PHARM(002038)2022-04-25 16:00Revenue and Profit Growth - Revenue and net profit both increased by over 10% in 2021, with multiple products entering IPO preparation stages and one company (Shouyao Holdings) submitting an IPO application[83] Product Sales Performance - Key products with sales exceeding 100 million RMB include Temozolomide Capsules (263 million RMB, up 109.18%), Human Alkaline Fibroblast Growth Factor (144 million RMB, up 45.83%), and Human Granulocyte Colony-Stimulating Factor (132 million RMB, up 6.48%)[89] - Anti-tumor and immunomodulatory products generated 733.74 million RMB in revenue, a 25.28% year-on-year increase, with Temozolomide, Liqisu, and Lenalidomide each exceeding 100 million RMB in sales[90] - Temozolomide Capsules accounted for 22.09% of total sales, making it the company's top-selling product[91] - Trauma repair products, including Human Fibroblast Growth Factor, achieved 144.46 million RMB in revenue, a 45.83% increase, contributing 12.11% to total sales[92] - Cardiovascular system drugs generated 115.49 million RMB in revenue, a 50.62% decline, primarily due to the removal of Compound Coenzyme from provincial medical insurance directories[95] Research and Development Progress - The company obtained production and clinical approvals for multiple products, including Rivaroxaban, and submitted several national invention patent applications, with two patents authorized[83] - Key R&D projects such as SL216 and SL205 progressed to pilot-scale production and preclinical trials, while SL219 initiated medium-scale research with domestic media and culture medium replacements[85] - The company continued to optimize cell culture and protein purification processes, replacing imported equipment and media with domestic alternatives to control industrial costs[84] Product Registration and Funding - Multiple products, including Dapagliflozin Tablets and Voriconazole Injection, were submitted for registration, and several diabetes treatment drugs received funding support for industrialization[85]